The totality of these results, the prevalence of sULBP6 in human tumors, and the immunosuppressive capacity of sULBP6 suggest that preventing sULBP6 from binding NKG2D may promote NK cell–mediated immuno surveillance and be a potential therapeutic intervention for cancer. The gene discussed is KLRK1; the disease is cancer.